← All trials
NCT03181360
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 12, 2017
- Primary completion
- Dec 31, 2019
- Completion date
- Dec 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University Hospital of North NorwayLead sponsor
- University Hospital of North NorwayOverall official - principal investigator
- Norwegian Health AssociationCollaborator
- Arctic University of NorwayStudy chair
- Arctic University of NorwayCollaborator
- Government of NorwayCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.